 |
|
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(1):146-162. Published online 2022 Aug 19 DOI: https://doi.org/10.3350/cmh.2022.0172
|
|
Citations to this article as recorded by
 Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy
Liandong Wu, Zhenggang Yang, Min Zheng
Journal of Viral Hepatitis.2024; 31(5): 255. CrossRef Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”
Yun-Fan Liaw
Clinical and Molecular Hepatology.2024; 30(2): 269. CrossRef Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy
Lorin Begré, Anders Boyd, Marie-Laure Plissonnier, Barbara Testoni, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Caroline Scholtès, Charles Béguelin, Jürgen K Rockstroh, Huldrych F Günthard, Alexandra Calmy, Matthias Cavassini, Hans H Hirsch, Patrick S
The Journal of Infectious Diseases.2024;[Epub] CrossRef Detection technology and clinical applications of serum viral products of hepatitis B virus infection
Ying Liu, Di Wu, Kui Zhang, Rongrong Ren, Yuxuan Liu, Shuya Zhang, Xuanyu Zhang, Jilin Cheng, Liping Chen, Jun Huang
Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial
Fahong Li, Lihong Qu, Yanhong Liu, Xiaoping Wu, Xun Qi, Jinyu Wang, Haoxiang Zhu, Feifei Yang, Zhongliang Shen, Yifei Guo, Yongmei Zhang, Jie Yu, Richeng Mao, Qiran Zhang, Fengdi Zhang, Liang Chen, Yuxian Huang, Xinxin Zhang, Qingxing Li, Wenhong Zhang, J
Journal of Hepatology.2024;[Epub] CrossRef Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2023; 29(1): 191. CrossRef New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
Young-Suk Lim
Clinical and Molecular Hepatology.2023; 29(1): 118. CrossRef Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip
Clinical and Molecular Hepatology.2023; 29(1): 113. CrossRef Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers
Lung-Yi Mak, Rex Wan-Hin Hui, Ka-Shing Cheung, James Fung, Wai-Kay Seto, Man-Fung Yuen
Expert Opinion on Drug Discovery.2023; 18(4): 401. CrossRef Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies
Georgia Zeng, Apostolos Koffas, Lung-Yi Mak, Upkar S. Gill, Patrick T.F. Kennedy
JHEP Reports.2023; 5(6): 100720. CrossRef The role of different viral biomarkers on the management of chronic hepatitis B
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2023; 29(2): 263. CrossRef Past, present, and future of long-term treatment for hepatitis B virus
Teresa Broquetas, José A Carrión
World Journal of Gastroenterology.2023; 29(25): 3964. CrossRef
|